Oric Pharmaceuticals (ORIC) Cash from Financing Activities (2019 - 2026)

Oric Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $61.1 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 555718.18% year-over-year to $61.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $306.4 million (up 19951.9% YoY) and the FY2025 annual result came in at $245.3 million, up 93.81% from the prior year.
• Cash from Financing Activities was $61.1 million for Q1 2026 at Oric Pharmaceuticals, up from $1.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $134.3 million in Q2 2025 and bottomed at $1000.0 in Q3 2022.
• A 5-year average of $34.0 million and a median of $695500.0 in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.0% — and 2026, when it soared 555718.18%.
• Oric Pharmaceuticals' Cash from Financing Activities stood at $24.8 million in 2022, then tumbled by 98.17% to $453000.0 in 2023, then climbed by 26.93% to $575000.0 in 2024, then jumped by 160.87% to $1.5 million in 2025, then jumped by 3976.0% to $61.1 million in 2026.
• Business Quant data shows ORIC's Cash from Financing Activities at $61.1 million in Q1 2026, $1.5 million in Q4 2025, and $109.5 million in Q3 2025.